APOE ε3/ε3 Genotype and Alzheimer's Disease Risk
No, the APOE ε3/ε3 genotype is NOT associated with increased risk of Alzheimer's disease—it represents the neutral, reference genotype against which other variants are compared.
Understanding APOE Genotypes and AD Risk
The APOE ε3/ε3 genotype is the most common variant in the population and serves as the baseline reference for AD risk assessment. The key risk stratification works as follows:
- APOE ε4 allele: Increases AD risk substantially 1
- APOE ε3 allele: Neutral/baseline risk (the reference standard)
- APOE ε2 allele: Protective, decreasing AD risk 2
The Evidence Framework
According to the 2011 joint practice guidelines from the American College of Medical Genetics and the National Society of Genetic Counselors, the ε4 allele is neither necessary nor sufficient to cause AD, which is why APOE genotyping for predictive purposes is not routinely offered clinically 1. The guidelines explicitly focus on ε4 as the risk allele, with no mention of ε3/ε3 conferring increased risk.
Recent large-scale research confirms this framework. A 2026 study examining over 460,000 participants found that 71.5-92.7% of AD cases were attributable to the presence of ε3 and ε4 alleles combined 3. However, this finding requires careful interpretation: the study used ε2/ε2 as the reference (protective) genotype, making ε3 appear to contribute to risk only when compared to this highly protective variant—not when compared to population baseline.
Clinical Risk Stratification
The 2018 Rotterdam Study provides the most clinically relevant risk data, demonstrating that APOE genotype dramatically modifies both cumulative risk and age at onset 4:
- Carriers homozygous for ε2 or heterozygous ε2/ε3 in low genetic risk score tertile: 4.1% AD risk by age 85
- Carriers homozygous for ε4 in high genetic risk score tertile: 62.7% AD risk by age 85
- This translates to an 18-29 year difference in age at onset between risk extremes 4
The ε3/ε3 genotype falls in the middle of this spectrum as the neutral reference point.
Important Caveats
The guidelines recommend against routine APOE testing for AD risk prediction due to 1:
- Low sensitivity and specificity
- Lack of preventive options
- Difficulty conveying probabilistic risk
- Gender and ethnic variations in risk expression
- Wide variability in reported odds ratios across studies
The REVEAL study found that while APOE disclosure didn't cause significant short-term psychological harm, approximately half of participants who correctly recalled their risk information believed their risk was different than disclosed, indicating the complexity of risk communication 1.
The Bottom Line
The ε3/ε3 genotype represents average population risk for AD, not increased risk. Only the ε4 allele confers increased risk, while ε2 is protective. The confusion in the question likely stems from studies using ε2/ε2 as a reference point, which makes ε3 appear risky by comparison—but this is a statistical artifact, not a clinically meaningful increased risk compared to the general population baseline.